

PROVIDER Update



CONTRACTUAL | MAY 2, 2018 | UPDATE 18-291 | 2 PAGES

Medication Trend Updates and Formulary Changes – 2nd Quarter 2018

This update includes information regarding patent expiration, HIV pre-exposure prophylaxis and post-exposure prevention, and changes to the CalViva Health formulary for the second quarter of 2018.

PATENT EXPIRATION FOR COMMONLY USED BRAND-NAME MEDICATIONS

Patents are granted by the United States Patent and Trademark Office along the development lifeline of a medication. Patents expire 20 years from the date of filing. Many factors can affect the duration of a patent. When a brand-name medication loses its patent, lower-priced generics enter the market. U.S. Food and Drug Administration (FDA)-approved generic drugs are made under the same rigorous standards as their brand-name counterparts and are bioequivalent, delivering the same amount of active ingredients into a patient's bloodstream in the same amount of time as their brand-name product. During the upcoming year, the key medications listed below are anticipated to be available as generic equivalents.

Medication Patent Expirations

	2018	2019
1ST QUARTER	Solodyn [®] (65 mg, 115 mg) [^]	Latuda, [®] [^] Ranexa [®]
2ND QUARTER	Adcirca, [®] NuvaRing, [®] Remodulin [®]	Levitra, [®] Lyrica, [®] Travatan Z, [®] Vesicare [®]
3RD QUARTER	Acanya, [®] [^] Sensipar [®]	Gilenya [®]
4TH QUARTER	Canasa, [®] Cialis, [®] Rapaflo [®]	Exjade [®] [^]

[^] Nonformulary

THIS UPDATE APPLIES TO
MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

PROVIDER SERVICES

1-888-893-1569
www.healthnet.com

HIV PRE-EXPOSURE PROPHYLAXIS AND POST-EXPOSURE PREVENTION FOR CALVIVA HEALTH MEMBERS

A recent notification from the Department of Health Care Services (DHCS) to health plans details issues regarding treatment delay and denials of pre-exposure prophylaxis (PrEP) and post-exposure prevention (PEP) medications used to prevent seroconversion to HIV. This has the potential to negatively impact beneficiaries, as the consequences of delaying or denying access to these medications can be life-altering.

DHCS would like managed care organizations (MCOs) to remind and educate their respective network providers, network pharmacies and staff about the scope of benefit and the proper submission of claims for these medications. These medications are considered a non-capitated, covered benefit and are billed through the Medi-Cal fee-for-service (FFS) system and not through the MCOs.

For all inquiries regarding HIV pre- or post-exposure prophylaxis, participating physician groups (PPGs) should advise that a Treatment Authorization Request (TAR) is not required by DHCS and should not delay treatment and/or prophylaxis.

Please share this information with any providers, pharmacies or staff that provide care for members that may be affected by this issue so that time-sensitive treatment is not delayed.

Additional information and resources for consumers and providers regarding PrEP and PEP are available at: www.cdc.gov/hiv/risk/index.html.

CHANGES TO THE CALVIVA HEALTH FORMULARY

The Pharmacy and Therapeutics Committee, which comprises practicing physicians, pharmacists and other health care professionals, reviews the medications on the CalViva Health formulary each quarter to determine which medications should remain on the formulary and which should be moved to a different status. A list of some recent changes is provided in the table below. The list contains prescription medications, their status, alternatives, and comments for the second quarter of 2018. The complete CalViva Health formulary and other pharmacy-related provider updates, revised prior authorization criteria and pharmacy forms are available at provider.healthnet.com under *Pharmacy Information*.

CALVIVA HEALTH FORMULARY CHANGES

Medication	Status	Formulary Alternative(s)	Comments
ORAL MEDICATIONS			
Odoactra™ House Dust Mite (<i>Dermatophagoides farinae</i> and <i>Dermatophagoides pteronyssinus</i>) Allergen Extract sublingual tablet	NF	Oral antihistamines: loratadine (Claritin®), cetirizine (Zyrtec®) Intranasal steroids: fluticasone (Flonase®) Nasal antihistamines: azelastine (Astelin®) Leukotriene inhibitor: montelukast (Singulair®)	Indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for immunoglobulin E (IgE) antibodies to <i>Dermatophagoides farinae</i> or <i>Dermatophagoides pteronyssinus</i> house dust mites or skin testing to licensed house dust mite allergen extracts in adults ages 18 through 65

**CCS = California Children's Services – Refer to www.dhcs.ca.gov for the local telephone number to determine a member's coverage eligibility.

-
- F indicates formulary.
 - NF indicates nonformulary.

ADDITIONAL INFORMATION

If you need additional information regarding the CalViva Health formulary, contact CalViva Health at 1-888-893-1569 or the pharmacy department by telephone at 1-800-867-6564, press #, or by fax at 1-800-977-8226.